| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2017-11-14 |
详情>>
股本变动：
变动后总股本1660.38万股
|
| 2017-11-14 |
详情>>
业绩披露：
2017年三季报(累计)每股收益-7.94美元,归母净利润-1.2亿美元,同比去年增长-141787.06%
|
| 2017-11-13 |
财报披露：
美东时间 2017-11-13 盘后发布财报
|
| 2017-08-09 |
详情>>
业绩披露：
2017年中报每股收益-6.63美元,归母净利润-9960.5万美元,同比去年增长-109.35%
|
| 2017-08-08 |
财报披露：
美东时间 2017-08-08 盘后发布财报
|
| 2017-05-30 |
股东大会：
将于2017-07-14召开股东大会
会议内容 ▼▲
- 1.To elect two (2) directors for a three-year term to expire at the 2020 annual meeting of stockholders.
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
4.To approve, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of our named executive officers.
5.To ratify the filing and effectiveness of the certificate of amendment to our certificate of incorporation filed with the Secretary of State of the State of Delaware on July 8, 2016 (the “July 2016 Certificate of Amendment”) and the one for ten reverse stock split of our common stock (the “2016 Reverse Stock Split”) that was effected thereby and became effective on July 11, 2016 (the “Amendment Ratification”).
6.To transact any other business that may properly come before our annual meeting.
|
| 2017-05-12 |
详情>>
业绩披露：
2017年一季报每股收益-4.67美元,归母净利润-6908.7万美元,同比去年增长-209.14%
|
| 2017-03-30 |
详情>>
业绩披露：
2016年年报每股收益-1.68美元,归母净利润-2452.4万美元,同比去年增长64.30%
|
| 2017-03-30 |
详情>>
业绩披露：
2014年年报每股收益-3.17美元,归母净利润-3752.5万美元,同比去年增长51.69%
|
| 2016-11-07 |
详情>>
业绩披露：
2016年三季报(累计)每股收益0.01美元,归母净利润8.50万美元,同比去年增长100.17%
|
| 2016-08-05 |
详情>>
业绩披露：
2016年中报每股收益-3.27美元,归母净利润-4757.8万美元,同比去年增长-19.73%
|
| 2016-08-05 |
详情>>
业绩披露：
2015年中报每股收益-3.19美元,归母净利润-3973.7万美元,同比去年增长19.57%
|
| 2016-07-08 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2016-05-27 |
股东大会：
将于2016-07-08召开股东大会
会议内容 ▼▲
- 1.To elect three (3) directors for a three-year term to expire at the 2019 annual meeting of stockholders.
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.
3.To approve our Amended and Restated 2007 Equity Incentive Award Plan.
4.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split.
5.To approve an amendment to our Amended and Restated Certificate of Incorporation, as amended, to increase our authorized shares of common stock.
6.To approve the issuance of our common stock upon the conversion of 0% Convertible Senior Secured Notes Due 2020 and warrants to purchase common stock.
7.To transact any other business that may properly come before our annual meeting.
|
| 2016-05-05 |
详情>>
业绩披露：
2016年一季报每股收益-0.15美元,归母净利润-2234.8万美元,同比去年增长-29.68%
|
| 2016-03-15 |
复牌提示：
2016-03-15 07:00:11 停牌，复牌日期 2016-03-15 07:30:00
|
| 2016-02-26 |
详情>>
业绩披露：
2015年年报每股收益-0.52美元,归母净利润-6868.7万美元,同比去年增长-83.04%
|
| 2015-11-09 |
详情>>
业绩披露：
2015年三季报(累计)每股收益-0.4美元,归母净利润-5087.8万美元,同比去年增长-33.43%
|
| 2015-04-22 |
股东大会：
将于2015-06-09召开股东大会
会议内容 ▼▲
- 1.To elect three (3) directors for a three-year term to expire at the 2018 annual meeting of stockholders.
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2015.
3.To transact any other business that may properly come before our annual meeting.
|
| 2014-04-30 |
股东大会：
将于2014-06-27召开股东大会
会议内容 ▼▲
- 1. To elect three (3) directors for a three-year term to expire at the 2017 annual meeting of stockholders.
2. To approve the flexible settlement feature in connection with the potential conversion of our Convertible Senior Notes, which could result in the issuance of an aggregate amount of shares of the company’s common stock equal to 20% or more of the amount of outstanding common stock at the time the Convertible Senior Notes were priced.
3. To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement.
4. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2014.
5. To transact any other business that may properly come before our annual meeting or any adjournment or postponement of the meeting.
|
| 2013-04-23 |
股东大会：
将于2013-06-05召开股东大会
会议内容 ▼▲
- 1. To elect three (3) directors for a three-year term to expire at the 2016 annual meeting of stockholders.
2. To approve the Orexigen Therapeutics, Inc. 2013 Employee Stock Purchase Plan.
3. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2013.
4. To transact any other business that may properly come before our annual meeting or any adjournment or postponement of the meeting.
|